NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company focusing on the development and commercialization of its non-antibiotic anti-infective products, announced today that the company will be exhibiting and seeking Partners for its breakthrough eye care product, Avenova™, at Arab Health 2015.
Held January 26-29, 2015, at the Dubai International Convention & Exhibition Centre in the United Arab Emirates, now in its 40th year, Arab Health 2015 is the largest healthcare conference in the world. Attended by more than 10,000 delegates from around the globe, Arab Health gathers international and regional medical practitioners together with leading manufacturers, wholesalers, dealers and distributors to network and exchange best practices.
“This conference will help us reach new and potentially large markets for Avenova,” said Dr. Ron Najafi, Chairman and CEO of NovaBay. “We are also inviting distributors and potential marketing partners from around the globe to visit our exhibit and discuss business opportunities.”
Building its direct field force of Medical Representatives to 35 across the U.S. over the past few months, NovaBay has already ramped up its Avenova sales efforts. NovaBay is targeting an estimated $500 million per year U.S. eye care market for managing the effects on the eyelids and eyelashes of such common eye conditions as blepharitis, meibomian gland dysfunction and associated dry eye syndrome.
Exhibiting at Arab Health is a key step at opening up markets in the Middle East, where hundreds of thousands of people are estimated to suffer from blepharitis or meibomian gland dysfunction. Avenova is also ideal for improving lid hygiene for contact lens wearers, whose numbers are increasing in the UAE and neighboring countries.
NovaBay will be exhibiting at Booth # 1E-12.
Avenova is the only eye care product to contain Neutrox, NovaBay’s proprietary pure hypochlorous acid (HOCl). HOCl is a naturally occurring substance produced by white blood cells to fight microbial invaders. Laboratory tests show Neutrox has potent antimicrobial activity and yet is non-toxic to mammalian cells. Neutrox neutralizes bacterial toxins in vitro. Avenova is uniquely suited for daily use by the millions of Americans who suffer from chronic eye conditions like blepharitis and dry eye. It is the only such product designed for continuous daily eyelid hygiene.
NovaBay’s Neutrox-containing cleanser was cleared by the U.S. Food and Drug Administration as a prescription medical device through the 510(k) process for cleansing and removal of microorganisms and debris from skin and wounds. It is distributed nationwide by McKesson Corporation and has been added to the Vision Source Independent Optometry Network. Vision Source is the largest independent optometry network in the country, representing 2,800 independent optometrist offices.
About NovaBay Pharmaceuticals, Inc.: Going Beyond Antibiotics®
NovaBay Pharmaceuticals is a biopharmaceutical company focusing on the development and commercialization of its non-antibiotic anti-infective products to address the unmet therapeutic needs of the global, topical anti-infective market with its two distinct product categories: FDA-cleared NEUTROX™ Family of Products: AVENOVA™ for the eye care market, NEUTROPHASE® for wound care and CELLERX™ for the dermatology market; and its AGANOCIDE® compounds, led by AURICLOSENE™. NovaBay is partnered in the U.S. and around the globe with: PBE, Inc. (U.S.), IHT, Inc. (U.S.), Galderma (France), Virbac (France), China Pioneer Pharma (China and Southeast Asia), Shin Poong Pharmaceuticals (Korea), Biopharm (North African and Middle East).
This news release contains “forward-looking statements.” These statements are based on management’s current expectations and involve risks and uncertainties, which may cause actual results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, commercial potential, and financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Other risks relating to the company and its products, including risks that could cause results to differ materially from those projected in the forward-looking statements in this press release, are detailed in NovaBay’s latest Form 10-K and Form 10-Q filings with the Securities and Exchange Commission, especially under the heading “Risk Factors.” NovaBay undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.
Stay informed on NovaBay’s progress:
Download our Mobile InvestorApp from the Apple Store or Google Play
Like us on Facebook
Follow us on Twitter
Connect with NovaBay on LinkedIn
Join us on Google+
Visit NovaBay’s Website
For investor information, please contact:
Thomas J. Paulson
Chief Financial Officer
Contact T. Paulson